Search
Betaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: BETAC FILM COATED TABLET 20 mg, BETOPTİC S %0,25 OFTALMİK SÜSPANSİYON, 5 MLSorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigational[A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: NEXAVAR TABLET 200 mg, Sorafenib TEVA 200 mg FilmtablettenAlanyl glutamine
go.drugbank.com/drugs/DB11876InvestigationalAlanyl Glutamine is under investigation in clinical trial NCT00338221 (Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition).
Products: DİPEPİTVEN %20 İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ, 100 ML, GLUTAVIVEN 20 G/100 ML IV INF. ICIN KONSANTRE COZELTI İÇEREN FLAKONClodronic acid
go.drugbank.com/drugs/DB00720ApprovedInvestigationalVet approved[A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910] … Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid].
Products: BONEFOS 800 MG TABLET, 60 ADET, Lodronat 520 mg - FilmtablettenBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsProducts: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersSynonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: RINVOQ 30 mg extended-release film coated tablets, Rinvoq 30 mg Uzatılmış Salımlı Tablet, 28 ADETSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction … Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: SİLODOPİN 4 MG KAPSÜL, 30 ADET, SİLODOPİN 8 MG KAPSÜL, 30 ADETFrovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. … Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsProducts: NEWART 2.5 MG TABLET, 12 ADET, MIGREX 2.5 MG FILM TABLET, 12 ADETIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid